United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares

Key Points

• Martine Rothblatt, CEO of United Therapeutics, sold 4,000 shares at an average price of $397.88, resulting in a total transaction of approximately $1.59 million, significantly reducing her holdings by 96.85%.
• The company reported Q2 earnings of $6.41 EPS, missing the consensus estimate of $6.80, with revenue of $798.60 million, which was also below analysts' expectations of $802.13 million.
• Several analysts have increased their price targets for United Therapeutics stock, with Jefferies setting a new target of $564.00 and Oppenheimer at $575.00, reflecting positive sentiment in the market.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the business's stock in a transaction on Monday, September 15th. The stock was sold at an average price of $397.88, for a total transaction of $1,591,520.00. Following the completion of the sale, the chief executive officer directly owned 130 shares of the company's stock, valued at approximately $51,724.40. The trade was a 96.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $403.11 on Tuesday. The firm has a market cap of $18.18 billion, a PE ratio of 15.73, a PEG ratio of 6.17 and a beta of 0.62. The firm has a fifty day moving average of $320.79 and a 200 day moving average of $307.95. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $436.95.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the previous year, the firm posted $5.85 earnings per share. The firm's revenue for the quarter was up 11.7% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Bank of America upped their price target on United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. cut their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Jefferies Financial Group upped their price target on United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. Oppenheimer increased their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Finally, HC Wainwright increased their price objective on United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a report on Friday, September 5th. Nine investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $438.85.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. F m Investments LLC increased its holdings in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company's stock valued at $741,000 after buying an additional 33 shares during the last quarter. HB Wealth Management LLC grew its holdings in United Therapeutics by 2.9% in the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock worth $355,000 after buying an additional 35 shares in the last quarter. Hohimer Wealth Management LLC grew its holdings in United Therapeutics by 0.3% in the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after buying an additional 37 shares in the last quarter. WealthCollab LLC grew its holdings in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after buying an additional 38 shares in the last quarter. Finally, Park Avenue Securities LLC lifted its position in United Therapeutics by 1.7% in the second quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company's stock worth $676,000 after purchasing an additional 39 shares during the period. Institutional investors and hedge funds own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.